Novonesis stock reflects merger-driven transformation as enzyme and microbial solutions scale up

Novonesis stock represents the listed biosolutions group formed from the combination of Novozymes A/S and Chr. Hansen Holding A/S, with the new entity tied to the legacy financial performance of the two Danish enzyme and microbial specialists as they build a larger platform for industrial and consumer applications in food, agriculture and health.

Legacy revenue above DKK 16 billion

Before the creation of Novonesis, the Novozymes business reported revenue of about DKK 17 billion in 2023 according to its last standalone annual figures, underlining the scale of the enzyme and microbial-solutions activities that have now been brought into the new combined group structure.

Chr. Hansen, which contributed strong positions in microbial-based cultures and probiotics, generated around DKK 3.7 billion in revenue in its 2022/23 financial year, so that together the two legacy businesses give Novonesis a revenue base that runs well above DKK 20 billion when their most recent annual periods are viewed on a combined basis.

Operating profitability in the billions of kroner

The legacy Novozymes operation delivered an operating profit on the order of DKK 4 billion in 2023, giving an operating margin in the mid-twenties percent range and showing that the enzyme and biosolutions model can support double-digit profitability at scale when volumes and pricing are aligned with specialty customer demand.

For the Chr. Hansen business, operating profit for its 2022/23 year was in the range of DKK 1 billion, which implies an operating margin around the high-teens to low-twenties percent area on its approximately DKK 3.7 billion of revenue, so that the combined profit base from the two companies offers Novonesis a solid level of earnings power to support investment and integration.

Enzymes and microbes in food and agriculture

The combined Novonesis portfolio centers on industrial enzymes, microbial cultures and fermentation-based technologies that improve yields and efficiency in industries such as baking, brewing, dairy, household care, bioenergy and agriculture, areas where its legacy businesses have supplied solutions to thousands of customers globally for many years.

Novonesis stock and listing framework

Novonesis stock is linked to the Danish listing framework established through the merger, with investors using the ISIN DK0060336014 as the primary security identifier while the group pursues long-term growth in biosolutions on the foundation of the multibillion-kroner revenue and operating profit generated by the former Novozymes and Chr. Hansen businesses.